Analysts expect Catalyst Biosciences Inc (NASDAQ:CBIO) to post ($1.20) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences posted earnings per share of ($0.54) during the same quarter last year, which suggests a negative year over year growth rate of 122.2%. The business is expected to report its next earnings results on Thursday, August 1st.

On average, analysts expect that Catalyst Biosciences will report full-year earnings of ($4.88) per share for the current fiscal year. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Catalyst Biosciences.

Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($0.18).

Separately, Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd.

CBIO traded down $0.01 on Friday, hitting $8.42. The company’s stock had a trading volume of 710 shares, compared to its average volume of 348,757. The stock’s 50 day simple moving average is $7.81. The stock has a market cap of $103.15 million, a price-to-earnings ratio of -3.15 and a beta of 2.19. Catalyst Biosciences has a 12 month low of $6.20 and a 12 month high of $13.36. The company has a current ratio of 24.94, a quick ratio of 24.94 and a debt-to-equity ratio of 0.02.

Large investors have recently made changes to their positions in the business. Rhumbline Advisers boosted its holdings in Catalyst Biosciences by 43.1% in the 4th quarter. Rhumbline Advisers now owns 17,000 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 5,120 shares during the period. Private Advisors LLC boosted its holdings in Catalyst Biosciences by 5.9% in the 1st quarter. Private Advisors LLC now owns 26,989 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 1,495 shares during the period. Rational Advisors LLC bought a new position in Catalyst Biosciences in the 1st quarter valued at $197,000. D. E. Shaw & Co. Inc. boosted its holdings in Catalyst Biosciences by 60.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 25,100 shares of the biopharmaceutical company’s stock valued at $198,000 after purchasing an additional 9,500 shares during the period. Finally, Requisite Energy Fund I LP bought a new position in Catalyst Biosciences in the 4th quarter valued at $256,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Featured Story: Support Level

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.